SeaStar Medical (NASDAQ:ICU – Get Free Report) posted its earnings results on Wednesday. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.08), Zacks reports. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%.
SeaStar Medical Trading Up 1.1%
NASDAQ:ICU traded up $0.02 during midday trading on Wednesday, hitting $1.92. 140,335 shares of the company were exchanged, compared to its average volume of 130,569. SeaStar Medical has a fifty-two week low of $1.84 and a fifty-two week high of $5.38. The company has a market capitalization of $10.21 million, a PE ratio of -0.49 and a beta of -1.07. The company has a fifty day simple moving average of $3.03 and a 200 day simple moving average of $3.29.
Wall Street Analyst Weigh In
ICU has been the subject of several recent research reports. Wall Street Zen raised shares of SeaStar Medical from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.00.
Get Our Latest Stock Analysis on ICU
SeaStar Medical Company Profile
SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function. Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy.
Further Reading
- Five stocks we like better than SeaStar Medical
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
